Full-Time

Senior Data Analyst

Posted on 5/9/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Data & Analytics (2)
,
Required Skills
Power BI
R
Machine Learning
Tableau
Requirements
  • Master’s degree OR Bachelor’s degree and 5 to 9 years of experience with one or more analytic visualization tools or languages (e.g., Tableau, Power BI)
Responsibilities
  • Support Cybersecurity and Digital Trust (CDT) metric reporting processes, ensuring accuracy and stakeholder alignment
  • Architect and deliver advanced dashboards that integrate strategic, operational, and tactical cybersecurity metrics using tools such as Tableau, Power BI, Spotfire, and R
  • Drive the design and implementation of on-demand reporting solutions that support high-impact decision-making across business and technical teams
  • Guide data discovery initiatives to identify reporting enhancements and develop scalable, optimized data storage solutions
  • Serve as a liaison with Amgen’s Security Metrics and Analytics team and stakeholders to evaluate and incorporate emerging technologies, including AI and machine learning
  • Align data and analytics initiatives with the program’s strategic vision, ensuring adoption of interoperable, cost-effective, and authorized technologies such as cloud platform
  • Collaborate with cross-functional teams including data analysts, data engineers, and data scientists to define requirements, translate business needs, and enhance cyber defense capabilities
  • Establish and maintain comprehensive documentation of metrics, data workflows, and reporting processes, ensuring knowledge transfer and audit readiness
  • Develop and maintain robust operational scripts, reusable code libraries, and data structures that strengthen security across complex, global computing environments
  • Engineer and operate automation scripts, test environments, and infrastructure-as-code solutions in support of advanced security objectives
  • Operate with initiative, effectively managing priorities in a dynamic environment with minimal oversight
  • Demonstrate strong leadership in communication, organization, and stakeholder engagement with a customer-focused mindset
Desired Qualifications
  • Hands-on experience with data analytics platforms and tools such as Tableau, Power BI
  • Proven ability to influence decision-making by clearly communicating complex security risks and data insights to both technical and non-technical stakeholders
  • Effective communicator with experience presenting to senior leadership and facilitating discussions with medium to large audiences
  • Clear understanding of relational and dimensional database modeling with the ability to design and support scalable data structures
  • Experience with Databricks
  • Strong programming skills in both compiled and interpreted languages (e.g., C, C++, Python, Ruby) with practical experience in Java, C#, and Visual Basic
  • Proficient in AI/ML concepts and tools, with a foundational understanding of algorithms and frameworks used for advanced analytics and anomaly detection
  • Demonstrated success working within Agile and DevOps teams, with practical experience in SCRUM practices and collaborative, iterative delivery
  • Skilled in DevOps and infrastructure automation using Ansible, Chef, Puppet, Docker, and Jenkins to build, test, and deploy cloud-based environments
  • Familiar with BI technology stacks and data analytics domains, with the ability to adapt to evolving enterprise architectures
  • Experienced in applying change management methodologies across complex, global environments involving multiple business units
  • Demonstrated adaptability and continuous learning in adopting new technologies, particularly in cloud, analytics, and cybersecurity
  • CompTIA Security+ (preferred)
  • Tool or Platform specific certification i.e., Tableau, SAS, Qlik, AWS (preferred)
  • Any SAFe Agile certification (preferred)
  • Initiative to explore alternate technology and approaches to solving problems
  • Skilled in breaking down problems, documenting problem statements, and estimating efforts
  • Excellent analytical and troubleshooting skills
  • Strong verbal and written communication skills
  • Ability to work effectively with global, virtual teams
  • High degree of initiative and self-motivation
  • Ability to manage multiple priorities successfully
  • Team-oriented, with a focus on achieving team goals

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Amgen who can refer or advise you

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.